191 related articles for article (PubMed ID: 30316610)
1. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G; Billon E; Baldini C; Massard C; Hilgers W; Delva R; Walz J; Pignot G; Rybikowski S; Dermeche S; Thomassin J; Brunelle S; Lavaud P; Loriot Y;
Eur J Cancer; 2018 Nov; 104():236-238. PubMed ID: 30316610
[No Abstract] [Full Text] [Related]
2. First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.
Parikh RB; Feld EK; Galsky MD; Adamson BJ; Cohen AB; Baxi SS; Boursi SB; Christodouleas JP; Vaughn DJ; Meropol NJ; Mamtani R
Future Oncol; 2020 Jan; 16(2):4341-4345. PubMed ID: 31840537
[No Abstract] [Full Text] [Related]
3. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
5. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
6. Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer.
Mehra KK; Petrylak DP
Oncology (Williston Park); 2018 Mar; 32(3):132-6. PubMed ID: 29548069
[No Abstract] [Full Text] [Related]
7. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
10. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Hsu MM; Balar AV
Clin Genitourin Cancer; 2019 Jun; 17(3):e618-e626. PubMed ID: 31005473
[TBL] [Abstract][Full Text] [Related]
14. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?
Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G
Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724
[No Abstract] [Full Text] [Related]
15. Making urothelial carcinomas less immune to immunotherapy.
Ramos JD; Yu EY
Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
[TBL] [Abstract][Full Text] [Related]
16. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
Dhariwal R; Pindoria N; Dasgupta P; Khan MS
BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
[No Abstract] [Full Text] [Related]
17. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
18. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Metastatic Urothelial Cancer in 2018.
Bellmunt J; Rodriguez-Vida A
JAMA Oncol; 2019 Jun; 5(6):904-905. PubMed ID: 30973581
[No Abstract] [Full Text] [Related]
20. Role of immunotherapy in bladder cancer.
Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
